Table 5. Comparison of published studies on pediatric craniopharyngioma.
*Calculated based on 22 eyes in our study.
VA: Visual acuity; U: Unavailable; NS: Not specified.
| Author (Year) | Our study (2019) | Drimtzias et al. (2014) [6] | Puget et al. (2007) [13] | Mediero et al. (2015) [8] | Lee et al. (2012) [11] | Jung et al. (2010) [12] | Bialer et al. (2012) [9] |
| Country | Malaysia | United Kingdom | France | Spain | Korea | Korea | Israel |
| Population | |||||||
| Adult | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Children | 11 | 20 | 66 | 10 | 27 | 17 | 20 |
| Mean age (SD) | 9.5 (4.2) | 7.3 | 7.4 | 5 | U | 12 | 6.5 (3.9) |
| Gender, n (%) | |||||||
| Male | 7 (63.6) | 10 (50.0) | 42 (63.6) | 6 (60.0) | 15 (55.6) | 12 (70.6) | 10 (50.0) |
| Female | 4 (36.4) | 10 (50.0) | 24 (36.4) | 4 (40.0) | 12 (44.4) | 5 (16.7) | 10 (50.0) |
| Systemic symptoms, n (%) | |||||||
| Headache | 8 (72.7) | 14 (70.0) | U | U | 18 (66.7) | 13 (76.5) | 6 (55.0) |
| Nausea/vomiting | 7 (63.6) | U | U | U | 6 (22.2) | NS | U |
| Motor deficit | 2 (18.2) | U | 8 (12.0) | U | U | 0 (0) | U |
| Seizure | 1 (9.1) | U | 3 (4.5) | U | U | 0 (0) | 1 (9.0) |
| Ocular symptoms, n (%) | |||||||
| Visual loss | 4 (36.4) | 6 (30.0) | 29 (44.0) | U | 12 (44.4) | 4 (23.5) | 1 (9.0) |
| Color vision defect | 1 (9.1) | U | U | U | U | 0 (0) | U |
| Diplopia/strabismus | 2 (18.2) | U | U | U | 4 (14.8) | 0 (0) | 3 (27.0) |
| VA presentation*, n (%) | |||||||
| 6/6–6/12 | 13 (59.0) | 19 (47.5) | U | U | 33 (61.1) | U | U |
| 6/15–6/60 | 3 (13.6) | 8 (20) | U | U | 14 (25.9) | U | U |
| Worse than 6/60 | 6 (27.3) | 13 (32.5) | U | U | 7 (13.0) | U | U |
| VA final*, n (%) | |||||||
| 6/6–6/12 | 11 (50.0) | 23 (57.5) | U | 12 (60) | 37 (68.5) | U | U |
| 6/15–6/60 | 1 (4.5) | 4 (10.0) | U | 3 (15.0) | 13 (24.1) | U | U |
| Worse than 6/60 | 10 (45.5) | 13 (32.5) | U | 5 (25.0) | 4 (7.4) | U | U |
| Fundus examination*, n (%) | |||||||
| Optic atrophy | 11 (50.0) | 12 (60.0) | U | 15 (75.0) | 14 (30.4) | U | 17 (42.5) |
| Papilledema | 2 (9.1) | 6 (30.0) | U | 0 (0) | 10 (21.7) | U | 6 (15.0) |
| Normal finding | 8 (36.4) | U | U | 5 (25.0) | 22 (47.8) | U | U |
| Visual field defect*, n (%) | |||||||
| Bilateral hemianopia | 2 (9.1) | 5 (35.7) | 10 (15.0) | 2 (20.0) | 3 (11.1) | U | 4 (26.7) |
| Unilateral hemianopia | 3 (13.6) | U | 9 (14.0) | 2 (20.0) | 3 (11.1) | U | 3 (20.0) |
| Central scotoma | 3 (13.6) | U | U | 0 (0) | 2 (7.4) | U | 0 (0) |
| Quadrantanopia | 2 (9.1) | U | 6 (9.0) | 0 (0) | 0 (0) | U | 1 (6.7) |
| Others | 1 (4.6) | U | 11 (17.0) | 2 (20.0) | 6 (22.2) | U | 1 (6.7) |
| Not performed/available | 5 (22.7) | U | 13 (20.0) | 3 (30.0) | 0 (0) | U | 0 (0) |
| Normal visual field | 6 (27.3) | 4 (28.5) | 23 (35.0) | 1 (10.0) | 13 (48.1) | U | 6 (40.0) |
| Imaging findings, n (%) | |||||||
| Suprasellar | 11 (100.0) | 20 (100.0) | U | U | 22 (100.0) | 10 (58.8) | U |
| Suprasellar + Intrasellar | 0 (0.0) | 0 (0) | U | U | 0 (0) | 7 (41.2) | U |
| Cystic | 7 (63.6) | 10 (50.0) | 6 (10.0) | U | 0 (0) | 11 (64.7) | U |
| Cystic and solid | 4 (36.4) | 10 (50.0) | U | U | 22 (100.0) | 6 (35.3) | U |
| Solid | 0 (0.0) | 0 (0) | U | U | 0 (0) | 0 (0) | U |
| Calcification | 5 (45.5) | 12 (60.0) | U | U | 18 (81.8) | 15 (88.2) | U |
| Hydrocephalus | U | U | 35 (53.0) | U | 3 (13.6) | U | U |
| Treatment, n (%) | |||||||
| Total resection | 8 (72.7) | 7 (35.0) | 33 (50.0) | 10 (100.0) | 27 (100.0) | 12 (70.6) | NS |
| Partial resection/biopsy | 1 (9.1) | 12 (60.0) | 33 (50.0) | 0 (0) | 0 (0) | 5 (29.4) | NS |
| No surgery | 2 (18.2) | 1 (5.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NS |
| Histopathology, n (%) | |||||||
| Squamous | 0 (0) | U | U | U | U | 0 (0) | U |
| Papillary | 0 (0) | U | U | U | U | 1 (5.9) | U |
| Adamantinoma | 7 (63.6) | U | 65 (98.5) | U | U | 16 (94.1) | U |
| Recurrence | 6 (54.5) | 11 (55.0) | 35 (53.0) | 2 (20.0) | 11 (40.7) | 2 (11.8) | U |